Mineralys Therapeutics (MLYS) Common Equity (2022 - 2026)

Mineralys Therapeutics has disclosed Common Equity across 5 years of filings, most recently posting $638.1 million for Q1 2026.

• Common Equity for Q1 2026 came in at $638.1 million, up 86.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $638.1 million (up 86.83% YoY), and the FY2025 annual result was $646.7 million, up 238.13% from the prior year.
• Common Equity came in at $638.1 million for Q1 2026 at Mineralys Therapeutics, down from $646.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $646.7 million in Q4 2025 to a low of -$52.3 million in Q4 2022.
• The 5-year median for Common Equity is $285.0 million (2023), against an average of $263.9 million.
• Across the five-year window, Common Equity soared 1070.88% in 2023 and declined 20.69% in 2024, its largest moves.
• Mineralys Therapeutics' Common Equity stood at -$52.3 million in 2022, then soared by 561.37% to $241.2 million in 2023, then retreated by 20.69% to $191.3 million in 2024, then soared by 238.13% to $646.7 million in 2025, then dropped by 1.32% to $638.1 million in 2026.
• The last three Common Equity figures came in at $638.1 million (Q1 2026), $646.7 million (Q4 2025), and $576.4 million (Q3 2025), per Business Quant data.